Now that Novavax has been added to the revamped COVID vaccines, you'll want to make sure to check on the changes to cost and more.

Novavax's fourth-quarter loss narrowed on Thursday, helped by reduced selling and administrative expenses of COVID-19 ...

Novavax ($NVAX) has recently seen a decrease in stock value, dropping after announcing Q4 results that missed revenue ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Effectiveness of 2024-25 COVID-19 vaccination against a COVID-19–associated ED/UC visit was 33% (95% confidence interval [CI] ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...

The current COVID-19 vaccine is 33% effective at preventing emergency department or urgent care visits among adults of all ages. It also is 45% to 46% effective at preventing hospitalizations in older ...

If passed, anyone who provides or administers a gene-based vaccine to another person would face a penalty of $500 per violation.

NVAX reports encouraging fourth-quarter results. It completes the sale of its Czech Republic manufacturing unit to Novo ...

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...